Document:

April 5, 2021 Initial Preliminary Data from Ongoing SWORD-1 Phase 1/2 Study of TPX-0046 Exhibit 10.1 

Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities,  plans and projected timelines, business strategy and plans, regulatory matters, objectives of management for future operations, market size and opportunity, our ability to complete certain milestones and our expectations regarding the relative benefits of our drug candidates versus competitive therapies. Words such as “believe,” “can”, “continue,” “anticipate,” “could,” “estimate,” “plan,” “predict,” “expect,” “intend,” “will,” “may,” “goal,” “upcoming,” “near term”, “milestone”, “potential,” “target” or the negative of these terms or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation: our preclinical studies and clinical trials may not be successful; regulatory authorities, including the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our drug candidates; we may decide, or regulatory authorities may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our drug candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; our drug candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates could delay or prevent regulatory approval or commercialization; the COVID-19 pandemic may disrupt our business and that of third parties on which we depend, including delaying or otherwise disrupting our research and development activities; and we may not be able to obtain additional financing. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Presentation is given. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This Presentation discusses a drug candidate that is under clinical study and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of this drug candidate for the use for which such drug candidate is being studied.
 2 

3
Compact macrocycle with a small binding interface

Potently inhibits wildtype RET and multiple RET mutations in cellular assays, demonstrates tumor regression in xenograft models

VEGF sparing, potential to provide improved safety over approved agents

Potential opportunity in TKI-naïve and TKI-pretreated patients following selective RET TKIs Retevmo and Gavreto, where there is no approved targeted therapy

 TPX-0046 is a Potent Next Generation RET Tyrosine Kinase Inhibitor 

4 Current SWORD-1 Phase 1/2 Study Design of TPX-0046 in Patients with Advanced Solid Tumors Harboring RET Fusion or Mutation Population
Adults with advanced solid tumors
RET fusion or mutation assessed by local testing
No limit on # of prior therapies
Prior RET TKI allowed
ECOG Performance Status 0 or 1
Asymptomatic CNS disease allowed
Design
3+3 with expansion allowed at doses where clinical activity is observed
Response evaluation by RECIST v1.1 10 mg QD
N=3 20 mg QD
N=4 Doses evaluated from 16 Dec 2019 to 10 Mar 2021
Dose evaluation ongoing  Phase 1 Dose Escalation (n=21) 10 mg BID N=4 30 mg QD
N=5 20 mg  30mg QD
N=3 20 mg BID N=2 Primary Objectives: Evaluate safety/tolerability and determine maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) Phase 2 (n~300) RP2D RET Fusion+ NSCLC
RET TKI-Naïve RET Fusion+ NSCLC
1 Prior RET TKI Treated RET Mutation+ Medullary Thyroid Carcinoma
RET TKI-Naïve RET Mutation+ Medullary Thyroid Carcinoma
1 Prior RET TKI Treated RET Fusion or Mutation+ Other Solid Tumors
RET TKI-Naïve RET Fusion or Mutation+ Other Solid Tumors
RET TKI-Pretreated 

5 Enrolled Subjects N=21
10 NSCLC, 11 MTC Evaluable Subjectsa N=14b

 TKI-Naïve (N=5)
3 NSCLC
2 MTC  TKI-Pretreated (N=9)
4 NSCLC
5 MTC NSCLC: non-small cell lung cancer; MTC: medullary thyroid carcinoma; TKI: tyrosine kinase inhibitor
Data Cutoff Date: March 10, 2021
a Patients with baseline measurable disease, received at least one dose of study drug, and at least one post-baseline assessment per RECIST v1.1
b As of data cut-off date, 5 patients off treatment and 2 patients on treatment awaiting first post-baseline assessment   Subject Disposition 

Demographics and Baseline Characteristics 6 * Selective TKI includes selpercatinib or pralsetinib
TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; MTC: medullary thyroid carcinoma.  Data Cutoff Date: March 10, 2021 

TPX-0046 Preliminary Safety Summary TPX-0046 has been generally well tolerated
Most AEs were Grade 1 or 2
Most common TEAE was dizziness
Infrequent dose modifications due to TEAE
4 (19%) patients with TEAEs that led to dose reduction
2 (10%) patients with TEAEs that led to drug discontinuation
MTD not reached; 1 DLT at 30 mg QD*
No treatment related Grade≥3 ALT/AST elevation
No treatment related hypertension, hemorrhagic events, QT prolongation, or ILD/pneumonitis of any Grade

Median duration of treatment: 7.9 weeks (range 1.6 – 51.0+ weeks) 7 TEAE: treatment emergent adverse event; TRAE: treatment related adverse event; MTD: maximum tolerated dose; DLT: dose-limiting toxicity. Data Cutoff Date: March 10, 2021 * DLT was reported as treatment related Grade 2 gait disturbance. 

TPX-0046 Preliminary Efficacy by Investigator Assessment 8 Of 5 RET TKI-naïve patients: 2 with confirmed PRs at 30 mg QD (DORs:  5.6 and 5.8+ months)
Of 9 RET TKI-pretreated patients: 2 have stable disease with tumor reductions of -27% and -17%
Both patients remained on treatment awaiting next scan TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; MTC: medullary thyroid carcinoma; DOR: duration of response.
Data Cutoff Date: March 10, 2021 # Patients remained on treatment 

TPX-0046 Preliminary Efficacy by Investigator Assessment  TKI-Pretreated Patients 9      Of 9 RET TKI-pretreated patients:
4 received 1 prior selective TKI
3 received 3 or more prior TKIs
2 received 2 prior TKIs TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; MTC: medullary thyroid carcinoma; DOR: duration of response.
Data Cutoff Date: March 10, 2021 # Patients remained on treatment Treated with 1 prior selective RET TKI 

TPX-0046 Duration of Treatment 10 PR: partial response; PD: progressive disease; NSCLC: non-small cell lung cancer; MTC: medullary thyroid carcinoma.
Data Cutoff Date: March 10, 2021 Duration of Treatment
TKI-Naïve (n=5): 8.9 to 51.0+ weeks
TKI-Pretreated (n=9): 5.1 to 41.3+ weeks 

Case 1: TKI-Naïve MTC Patient  Demographics
62 years old male with sporadic metastatic MTC
Post-thyroidectomy follow up evaluation showed rising tumor markers (doubling calcitonin and CEA over 2 months) and MRI revealed liver metastases
Molecular Characteristics
RET D631-L633delInsE
Prior Treatment History
None
TPX-0046 Treatment Course
Received TPX-0046 at 30 mg QD
Best response: confirmed PR (-42% SLD); patient remained on treatment in Cycle 11 at time of data cutoff
 Baseline Cycle 11 11 Tumor Markers MTC: medullary thyroid carcinoma; CEA: carcinoembryonic antigen; QD: once daily; SLD: sum of longest diameter 

Demographics
54-year old male with metastatic NSCLC
Molecular Characteristics
KIF5B-RET by NGS
Prior Treatment History
1) Selpercatinib for 9 months
2) Carboplatin/ Pemetrexed/ Pembrolizumab
TPX-0046 Treatment Course
Received TPX-0046 at 30 mg QD
Best response: SD (−27% SLD); patient remained on treatment in Cycle 11 at time of data cutoff Case 2: TKI-Pretreated NSCLC Patient  NSCLC: non-small cell lung cancer; NGS: next-generation sequencing; QD: once daily;  SD: stable disease; SLD: sum of longest diameter 12 Baseline Cycle 11  

TPX-0046 Phase 1 Early Data Key Takeaways TPX-0046 has an encouraging emerging profile and dose evaluations are ongoing
Majority of patients were heavily pretreated with nearly half of patients having received >3 prior therapies
TPX-0046 was generally well tolerated.  MTD was not reached with 1 DLT at 30 mg QD
Among 14 efficacy evaluable patients, preliminary data show clinical activity
TKI-Naïve:  confirmed PRs (NSCLC and MTC)
TKI-Pretreated:  SDs with tumor reductions (-27% and -17%; both remained on treatment awaiting next scan)
Protocol amendment planned to evaluate TPX-0046 in Phase 1 expansion cohorts
 13 Data Cutoff Date: March 10, 2021 

Next Steps Evaluating multiple doses and schedules to determine RP2D
Modifying Phase 1 protocol to evaluate TPX-0046 in expansion cohorts in up to 75 patients:
 14
Currently evaluating 30 mg QD, 2040 mg QD, and 20 mg BID dose levels* RP2D Phase 1 Dose Finding * Additional doses and/or schedules may be explored. RP2D: recommended phase 2 dose 

April 5, 2021 Initial Preliminary Data from Ongoing SWORD-1 Phase 1/2 Study of TPX-0046EX-10.3

 Exhibit 10.3 

EG Acquisition Corp. 
 375 Park
Avenue 24th Floor 
 New York, NY 10152 

January 29, 2021 
 EG Sponsor LLC 

375 Park Avenue 24th Floor 
 New York, NY 10152 

 

	RE:	 Securities Subscription Agreement 

Ladies and Gentlemen: 
 We are pleased to accept
the offer EG Sponsor LLC, a Delaware limited liability company (the “Subscriber” or “you”), has made to subscribe for and purchase 5,750,000 shares of Class B common stock, $0.0001 par value per share (the
“Shares”), up to 750,000 Shares of which are subject to surrender and cancellation by you if the underwriters of the initial public offering (“IPO”) of units of EG Acquisition Corp., a Delaware corporation (the
“Company”), do not fully exercise their over-allotment option (the “Over-allotment Option”). The terms (this “Agreement”) on which the Company is willing to sell the Shares to the Subscriber, and
the Company and the Subscriber’s agreements regarding such Shares, are as follows: 
 1. Subscription and Purchase of Shares.
For the sum of $25,000 (the “Purchase Price”), which the Company acknowledges receiving in cash, the Company hereby sells and issues the Shares to the Subscriber, and the Subscriber hereby subscribes for and purchases the Shares
from the Company, subject to the surrender and cancellation provisions of Section 3 below, on the terms and subject to the conditions set forth in this Agreement. Concurrently with the Subscriber’s execution of this Agreement, the Company
shall effect such delivery in book-entry form. 
 2. Representations, Warranties and Agreements. 

2.1. Subscriber’s Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber, the
Subscriber hereby represents and warrants to the Company and agrees with the Company as follows: 
 2.1.1. No Government Recommendation
or Approval. The Subscriber understands that no federal or state agency has passed upon or made any recommendation or endorsement of the offering of the Shares. 

2.1.2. No Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the
transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the limited liability company agreement of the Subscriber, (ii) any agreement, indenture or instrument to which the Subscriber is a party,
(iii) any law, statute, rule or regulation to which the Subscriber is subject, or (iv) any agreement, order, judgment or decree to which the Subscriber is subject. 

 2.1.3. Formation and Registration and Authority. The Subscriber is a Delaware
limited liability company, validly existing and possessing all requisite power and authority necessary to carry out the transactions contemplated by this Agreement. Upon execution and delivery by you, this Agreement will be a legal, valid and
binding agreement of Subscriber, enforceable against Subscriber in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of
creditors’ rights generally and subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity). 

2.1.4. Experience, Financial Capability and Suitability. Subscriber is: (i) sophisticated in financial matters and is able to
evaluate the risks and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite period of time because the Shares have not been registered under the Securities Act (as
defined below) and therefore cannot be resold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber is capable of evaluating the merits and risks of its investment in the Company and
has the capacity to protect its own interests. Subscriber must bear the economic risk of this investment until the Shares are sold pursuant to: (x) an effective registration statement under the Securities Act of 1933, as amended (the
“Securities Act”) or (y) an exemption from registration available with respect to such sale. Subscriber is able to bear the economic risks of an investment in the Shares and to afford a complete loss of Subscriber’s
investment in the Shares. 
 2.1.5. Access to Information; Independent Investigation. Prior to the execution of this Agreement, the
Subscriber has had the opportunity to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the finances, operations, business and prospects of the Company, and the opportunity
to obtain additional information to verify the accuracy of all information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber’s own knowledge and understanding of the Company and its business
based upon Subscriber’s own due diligence investigation and the information furnished pursuant to this paragraph. Subscriber understands that no person has been authorized to give any information or to make any representations which were not
furnished pursuant to this Section 2 and Subscriber has not relied on any other representations or information in making its investment decision, whether written or oral, relating to the Company, its operations or its prospects. 

2.1.6. Accredited Investor. The Subscriber represents that it is an “accredited investor” as such term is defined in
Rule 501(a) of Regulation D under the Securities Act and acknowledges the sale contemplated hereby is being made in reliance on a private placement exemption to “accredited investors” within the meaning of Section 501(a) of
Regulation D under the Securities Act or similar exemptions under federal and state law. 
 2.1.7. Investment Purposes. The
Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber’s own account and not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof that would result
in a violation of the Securities Act. The Subscriber did not enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 of Regulation D under the Securities Act. 

 2.1.8. Restrictions on Transfer; Shell Company. The Subscriber understands the
Shares are being offered in a transaction not involving a public offering within the meaning of the Securities Act. Subscriber understands the Shares will be “restricted securities” as defined in Rule 144(a)(3) under the Securities
Act. If in the future the Subscriber decides to offer, resell, pledge or otherwise transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only in accordance with the provisions of Section 5 hereof. Subscriber
agrees that if any transfer of its Shares or any interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber may be required to deliver to the Company an opinion of counsel satisfactory to the Company. Absent
registration or an exemption, the Subscriber agrees not to offer, resell, pledge or otherwise transfer the Shares. Subscriber further acknowledges that because the Company is a shell company, Rule 144 may not be available to the Subscriber for the
resale of the Shares until one year following consummation of the initial business combination of the Company, despite technical compliance with the certain requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.

 2.1.9. No Governmental Consents. No governmental, administrative or other third party consents or approvals are required or
necessary on the part of Subscriber in connection with the transactions contemplated by this Agreement. 
 2.2. Company’s
Representations, Warranties and Agreements. To induce the Subscriber to subscribe for and purchase the Shares, the Company hereby represents and warrants to the Subscriber and agrees with the Subscriber as follows: 

2.2.1. Incorporation and Corporate Power. The Company is a Delaware corporation and is qualified to do business in every jurisdiction
in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to
carry out the transactions contemplated by this Agreement. 
 2.2.2. No Conflicts. The execution, delivery and performance of this
Agreement and the consummation by the Company of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the certificate of incorporation or bylaws of the Company, (ii) any agreement, indenture
or instrument to which the Company is a party, (iii) any law, statute, rule or regulation to which the Company is subject, or (iv) any agreement, order, judgment or decree to which the Company is subject. 

2.2.3. Title to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Shares will be duly and
validly issued as fully paid and non-assessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Subscriber will have or receive good title to the Shares, free and clear of all
liens, claims and encumbrances of any kind, other than (a) transfer restrictions hereunder and other agreements to which the Shares may be subject which have been notified to the Subscriber in writing, (b) transfer restrictions under
federal and state securities laws, and (c) liens, claims or encumbrances imposed due to the actions of the Subscriber. 

 2.2.4. No Adverse Actions. There are no actions, suits, investigations or
proceedings pending, threatened against or affecting the Company which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or (ii) question the validity or legality
of any transactions or seek to recover damages or to obtain other relief in connection with any transactions. 
 3. Surrender and
Cancellation of Shares. 
 3.1. Partial or No Exercise of the Over-allotment Option. In the event the Over-allotment Option
granted to the representative of the underwriters of the IPO is not exercised in full, the Subscriber acknowledges and agrees that it (and, if applicable, any transferee of Shares) shall surrender any and all rights to such number of Shares (up to
an aggregate of 750,000 Shares and pro rata based upon the percentage of the Over-allotment Option exercised) such that immediately following such surrender, the Subscriber (and any such transferees) will own an aggregate number of Shares (not
including shares of common stock issuable upon exercise of any warrants or any shares of common stock subscribed for and purchased by Subscriber in the IPO or in the aftermarket) equal to 20% of the issued and outstanding shares of common stock of
the Company immediately following the IPO. 
 3.2. Termination of Rights as Shareholder. If any of the Shares are surrendered and
cancelled in accordance with this Section 3, then after such time the Subscriber (or successor in interest) shall no longer have any rights as a holder of such Shares, and the Company shall take such action as is appropriate to cancel such
Shares. 
 3.3. No Share Certificates. The Shares will be issued in uncertificated form. 

4. Waiver of Liquidation Distributions; Redemption Rights. In connection with the Shares subscribed for and purchased pursuant to this
Agreement, the Subscriber hereby waives any and all right, title, interest or claim of any kind in or to any distributions by the Company from the trust account which will be established for the benefit of the Company’s public shareholders and
into which substantially all of the proceeds of the IPO will be deposited (the “Trust Account”), in the event of a liquidation of the Company upon the Company’s failure to timely complete an initial business combination. For
purposes of clarity, in the event the Subscriber subscribes for and purchases shares of common stock in the IPO or in the aftermarket, any additional shares of common stock so subscribed for and purchased shall be eligible to receive any liquidating
distributions by the Company. However, in no event will the Subscriber have the right to redeem any shares of common stock into funds held in the Trust Account upon the successful completion of an initial business combination. 

5. Restrictions on Transfer. 

5.1. Securities Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an
“Insider Letter”) to be dated as of the closing of the IPO by and between Subscriber and the Company, Subscriber agrees not to sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior

 
thereto (a) a registration statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed to be transferred shall then be
effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company, that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules
promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws. 
 5.2. Lock-up. Subscriber acknowledges that the Shares will be subject to lock-up provisions contained in the Insider Letter. 

5.3. Additional Shares or Substituted Securities. In the event of the declaration of a stock dividend, the declaration of a special
dividend payable in a form other than Shares, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company’s outstanding Shares without
receipt of consideration, any new, substituted or additional securities or other property which are by reason of such transaction distributed with respect to any Shares subject to this Section 5 or into which such Shares thereby become
convertible shall immediately be subject to this Section 5 and Section 3. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number or class of Shares subject to this Section 5 and
Section 3. 
 5.4. Registration Rights. The Subscriber acknowledges that the Shares are being subscribed for and purchased
pursuant to an exemption from the registration requirements of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to a Registration Rights Agreement to be entered into with the
Company prior to the closing of the IPO. 
 6. Other Agreements. 

6.1. Further Assurances. The Subscriber agrees to execute such further instruments and to take such further action as may reasonably be
necessary to carry out the intent of this Agreement. 
 6.2. Notices. All notices, statements or other documents which are required or
contemplated by this Agreement shall be in writing and delivered: (i) personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing,
(ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided to
such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day
following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail. 

 6.3. Entire Agreement. This Agreement, together with that certain Insider Letter to
be entered into between Subscriber and the Company, substantially in the form to be filed as an exhibit to the Registration Statement on Form S-1 associated with the Company’s IPO, embodies the entire
agreement and understanding between the Subscriber and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation,
warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 

6.4. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement
executed by all parties hereto. 
 6.5. Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for
the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other
terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 

6.6. Assignment. The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written
consent of the other party. 
 6.7. Benefit. All statements, representations, warranties, covenants and agreements in this Agreement
shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties
hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement. 
 6.8. Governing Law. This
Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of Delaware applicable to contracts wholly performed within the borders of such state, without giving effect to the
conflict of law principles thereof. The parties hereto irrevocably submit to the exclusive jurisdiction of the Chancery Court of the State of Delaware over any suit, action or proceeding arising out of or relating to this Agreement. To the fullest
extent they may effectively do so under applicable law, the parties hereto irrevocably waive and agree not to assert, by way of motion, as a defense or otherwise, any claim that they are not subject to the jurisdiction of any such court, any
objection that they may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an
inconvenient forum. 
 6.9. Severability. In the event that any court of competent jurisdiction shall determine that any provision, or
any portion thereof, contained in this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it reasonable and enforceable, and as so limited shall remain in
full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect. 

 6.10. No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto
in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single or partial exercise of any right, power or
remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power
or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall
entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any
circumstances without such notice or demand. 
 6.11. Survival of Representations and Warranties. All representations and warranties
made by the parties hereto in this Agreement or in any other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof and any investigations made by or on behalf of the parties. 

6.12. No Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial
consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to create any liability on the other. Each of the parties hereto agrees to indemnify and hold the other harmless from any
claim or demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming to have been employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any
such claim. 
 6.13. Headings and Captions. The headings and captions of the various sections of this Agreement are for convenience of
reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. 
 6.14.
Counterparts. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a
valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. 

6.15. Construction. The words “include,” “includes,” and “including” will be deemed to be followed by
“without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise
requires. The words “this Agreement,” “herein,” “hereof,” “hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular section unless expressly so
limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or

 
covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of
specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant. 

6.16. Mutual Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject
to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. 
 7.
Voting and Redemption of Shares. The Subscriber agrees to vote the Shares in favor of an initial business combination that the Company negotiates and submits for approval to the Company’s shareholders and shall not seek redemption or
repurchase with respect to such Shares. Additionally, the Subscriber agrees not to tender any Shares in connection with a tender offer presented to the Company’s shareholders in connection with an initial business combination negotiated by the
Company. 
 [Signature Page Follows] 

 If the foregoing accurately sets forth our understanding and agreement, please sign the
enclosed copy of this Agreement and return it to us. 
  

			
	Very truly yours,
	
	EG ACQUISITION CORP.
		
	By:	 	 /s/ Sophia Mullen

		 	Name: Sophia Mullen
		 	Title:   President

  

			
	Accepted and agreed this 29th day of January, 2021
	
	EG SPONSOR LLC
		
	By:	 	 /s/ Matthew Lux

		 	Name: Matthew Lux
		 	Title:   Chief Operating Officer

  

  
 [Signature Page to
Securities Subscription Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]